Group 1: Lifetime Brands (LCUT) - Lifetime Brands is a leading designer, marketer, and distributor of kitchenware with a Zacks Rank 1 (Strong Buy) [1] - The Zacks Consensus Estimate for its current year earnings has increased by 35.6% over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 7.54, significantly lower than the industry average of 13.90, and possesses a Value Score of A [2] Group 2: Afya (AFYA) - Afya is a medical education group primarily operating in Brazil, also carrying a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 0.6% over the last 60 days [2] - The company has a price-to-earnings ratio (P/E) of 8.23 compared to the industry average of 15.60, and it holds a Value Score of A [2] Group 3: Jones Lang LaSalle (JLL) - Jones Lang LaSalle is a leading full-service real estate firm providing corporate, financial, and investment management services globally, with a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 7.3% over the last 60 days [3] - The company has a price-to-earnings ratio (P/E) of 13.50, which is lower than the industry average of 25.50, and it also possesses a Value Score of A [3]

Core Viewpoint - Afya (AFYA) is showing solid improvement in earnings estimates, which may lead to continued short-term price momentum and a favorable earnings outlook [1][2]. Earnings Estimate Revisions - The trend in estimate revisions reflects growing analyst optimism regarding Afya's earnings prospects, which is expected to positively impact its stock price [2]. - The current-quarter earnings estimate is $0.54 per share, representing a -1.8% change from the previous year, but the Zacks Consensus Estimate has increased by 8.16% over the last 30 days due to one upward revision [5]. - For the full year, the earnings estimate is $1.79 per share, showing a +2.3% change from the year-ago figure, with the consensus estimate increasing by 8.44% over the same period [6][7]. Zacks Rank - Afya currently holds a Zacks Rank 2 (Buy), indicating promising estimate revisions and a strong potential for outperformance compared to the S&P 500 [8]. - The Zacks Rank system has a proven track record, with Zacks 1 Ranked stocks averaging a +25% annual return since 2008 [3]. Stock Performance - Afya shares have increased by 6% over the past four weeks, suggesting investor confidence in its earnings growth prospects [9].

We have two more minutes still, but should we see if it's there. >> For Addie Rosa, this is a moment years in the making. The single mom is also a med school student.And this notification revealing whether she matched into a residency program. >> Mommy's going to be a doctor. You're going to be on my list.>> Oh, I'm so happy. >> I started second semester when she was 4 weeks old. And it was definitely the hardest year of my life.It's just incredible how how much my community has shown up for me and made it ...

Core Insights - Afya Limited reported strong financial results for Q4 and FY 2025, achieving significant growth in net income, adjusted EBITDA, and revenue, reflecting the robustness of its business model and operational execution [1] Financial Highlights - Q4 2025 net income increased by 13.7% YoY to R$175.4 million, while adjusted net income rose by 6.3% YoY to R$205.7 million, with basic EPS growth of 14.9% [1] - FY 2025 net income reached R$768.4 million, an 18.4% increase YoY, and adjusted net income was R$901.7 million, up 9.9% YoY, with basic EPS growth of 18.7% [1] - Q4 2025 revenue grew by 7.5% YoY to R$913.0 million, and FY 2025 revenue increased by 11.9% YoY to R$3,697.3 million [1] Adjusted EBITDA and Margins - Q4 2025 adjusted EBITDA rose by 6.1% YoY to R$388.5 million, with an adjusted EBITDA margin of 42.6%, a decrease of 50 bps YoY [1] - FY 2025 adjusted EBITDA increased by 15.4% YoY to R$1,680.3 million, with an adjusted EBITDA margin of 45.4%, an increase of 130 bps YoY [1] User Growth and Ecosystem - Afya's ecosystem reached approximately 301,000 users, with a significant increase in the number of continuing education students by 8.9% and a 9.4% growth in B2P revenue for medical practice solutions [1] - The company aims to strengthen its position as a leading medical education provider in Brazil, focusing on expanding its audience and enhancing digital products [1] Capital Allocation and Shareholder Returns - Afya's strong cash generation allowed for a record free cash flow of R$1,056 million and a solid cash position of R$1,125.4 million as of December 31, 2025 [1] - The Board of Directors approved a new share repurchase program for up to 4,000,000 Class A common shares and declared a cash dividend of R$307.4 million, representing 40% of the consolidated net income for 2025 [1] 2026 Guidance - For FY 2026, Afya expects revenue to range between R$3,950 million and R$4,100 million, and adjusted EBITDA to be between R$1,700 million and R$1,800 million, excluding any acquisitions [1]

Core Insights - Afya reported strong financial performance for the fourth quarter and the full year, with significant year-over-year growth in revenue and adjusted EBITDA, reflecting the company's successful strategy in medical education and ecosystem integration [1][2][3] Financial Performance - Fourth-quarter revenue reached BRL 913 million, an 8% increase year-over-year, while adjusted EBITDA rose 6% to BRL 389 million, with an adjusted EBITDA margin of 42.6%, down 50 basis points from the previous year [1] - For the full year, Afya's revenue was BRL 3,697 million, up 12% year-over-year, and adjusted EBITDA was BRL 1,680 million, representing growth of over 50% year-over-year, with an adjusted EBITDA margin of 45.4%, up 130 basis points [2][6] - The company reported net income of BRL 768.4 million, an 18% increase, with basic EPS of BRL 8.32, up 19% [2] Strategic Initiatives - Afya is focused on transforming medical education in Brazil, achieving its seventh consecutive year of meeting or exceeding guidance since the second half of 2018 [3] - The company is prioritizing ecosystem integration and expansion, targeting approximately 200 medical seats per year through M&A, and has recently added 60 acquired seats along with authorization for 102 new seats [4][11] Cash Generation and Shareholder Returns - Afya demonstrated strong cash generation with operating cash flow of BRL 1,548 million, a conversion rate of 93.7%, and net debt of BRL 1,369 million, resulting in a leverage ratio of approximately 0.8x [5][14] - A cash dividend of BRL 307.4 million was announced, equating to BRL 3.45 per share, representing 40% of 2025 net income, with plans to return about 50% of consolidated net income to shareholders [15] Operational Highlights - The company maintained a leadership position in medical education with 3,755 approved medical seats and over 25,000 undergraduate medical students, a 5% increase year-over-year [7] - Continuing education revenue for the year was BRL 284 million, up 11% year-over-year, with a gross margin expansion of 363 basis points [8] - In medical practice solutions, revenue was BRL 171 million, a 6% increase year-over-year, with 196,000 paying users and a broader ecosystem reaching 301,000 active users [9] Future Guidance and Investment Plans - Afya provided guidance for 2026, projecting revenue between BRL 3.95 billion and BRL 4.1 billion and adjusted EBITDA between BRL 1.7 billion and BRL 1.8 billion, while cautioning about margin pressure due to planned investments [6][17] - The company plans to enhance integration across its services and products, aiming for improved B2B monetization and a unified experience for users [18][19]

Financial Data and Key Metrics Changes - Revenue for the 12-month period grew 12% year-over-year, reaching BRL 3,697 million, with adjusted EBITDA growth of over 50% year-over-year, reaching BRL 1,680 million [4][5] - Adjusted EBITDA margin for the same period reached 45.4%, an increase of 130 basis points over last year [4] - Net income reached BRL 768.4 million, a growth of 18% year-over-year, with basic EPS reaching BRL 8.32, 19% higher than last year [5][26] - Cash flow from operating activities ended the 12-month period with BRL 1,548 million, over 6% higher than last year, with a cash conversion of 93.7% [4][25] Business Line Data and Key Metrics Changes - The undergraduate segment saw a 5% growth in the number of medical students, reaching over 25,000, with approved medical seats increasing by 5% [19] - Continuing education revenue grew 11% year-over-year, reaching BRL 284 million, with B2B revenue growth of 48% [7][22] - Medical practice solutions revenue increased by 6% year-over-year, reaching BRL 171 million [7][23] Market Data and Key Metrics Changes - The ecosystem reached 301,000 active users, reflecting strong engagement among physicians and medical students across Brazil [7] - The number of active payers in medical practice solutions reached 196,000, indicating growth in the user base [23] Company Strategy and Development Direction - The company aims to strengthen its position across the entire physician lifecycle, expanding audience reach and deepening engagement [11][12] - Investments will focus on integrating products and services for a unified experience, enhancing technology and data capabilities [12][15] - The strategy includes maintaining a low customer acquisition cost for undergraduate students, preserving competitive advantage [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another strong year in 2026, with revenue expected to range between BRL 3.95 billion and BRL 4.1 billion [16] - The company does not foresee any material impact from Enamed on its 2026 guidance, with expectations for improved results in the future [17][46] - The focus remains on creating value across the ecosystem, supporting ongoing medical learning and improving the medical journey [32] Other Important Information - A cash dividend of BRL 307.4 million was announced, representing 40% of the 2025 net income, payable in April 2026 [10] - The company maintains a conservative leverage profile with net debt at 0.8 times adjusted EBITDA [9][29] Q&A Session Summary Question: Transformation in Continuing Education and Medical Practice Solutions - The company plans to integrate products and services for a unified experience, enhancing technology and creating a membership concept [35][37] - Investments will focus on leveraging B2B experiences and monetizing offerings within the ecosystem [38] Question: Progress on Enamed and PROFIMED - Management does not foresee any impact from Enamed on 2026, with strong occupancy expected [45] - Preparations for new campuses include running simulations to improve performance [46][48] Question: M&A Strategy - The company aims to add 200 seats per year through M&A, targeting institutions with over 60% revenue from medicine programs [50] Question: Operational Expenses and CapEx - Operational expenses increased only 1% year-over-year, with a significant increase in intangible assets due to new investments [53][55] - The EBITDA margin guidance for 2026 reflects investments in continuing education and medical practice solutions [56][57] Question: Capital Allocation Priorities - The company prioritizes free cash flow generation, with a balanced approach to dividends, share buybacks, and acquisitions [61][63] - Future capital allocation will focus on maintaining a strong free cash flow while funding growth opportunities [66]

Core Viewpoint - Afya Limited has announced a cash dividend distribution of R$307.4 million, which constitutes 40% of its consolidated net income for the year ended December [1] Group 1: Company Announcement - The Board of Directors of Afya Limited approved the second distribution of a cash dividend [1] - The dividend distribution is scheduled for March 12, 2026 [1] - The amount of the dividend is R$307.4 million [1]

EXPERIENCE THE BEST IN MEDICINE INSTITUTIONAL PRESENTATION FY25 SAFE HARBOR This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements other than statements of historical fact, could be deemed forward-looking, including risks and uncertainties related to statements about our competition; our ability to attract, upsell and retain students; our ability to increase ...

A very good afternoon to one and all you. I am Dr. . Vijay Goadj a ENT doctor by enforcement.H how many of you want to become engineers. Lift your hand. Even I wanted to become an engineer.Fortunately or unfortunately I was forced into medicine. Okay, let's take it up like this. Then you get angry with your father.Why you're forcing me into something which I don't like. And every time remember all of you. It's not like an advice.Okay, just take it home as a message. How many of you get angry. Just lift your ...

Core Viewpoint - The provincial government report emphasizes the development of the "silver economy" as a new opportunity for economic transformation in response to the challenges of an aging population [3]. Group 1: Demographic Changes - By the end of 2025, the population aged 60 and above in China is projected to exceed 320 million, accounting for 23% of the total population, indicating a rapid acceleration of the aging process [3][4]. - Luzhou has entered a moderately aging society as of 2022, with an expected elderly population of 1.1515 million by the end of 2024, also representing 23% of the registered population [4]. Group 2: Strategic Recommendations - It is proposed to establish Luzhou as a national-level demonstration zone for high-quality development of the silver economy, providing a "Sichuan solution" to address related challenges nationwide [4]. - Luzhou's geographical location at the junction of Sichuan, Chongqing, Guizhou, and Yunnan is seen as a strategic advantage for developing the silver economy [4]. Group 3: Institutional and Educational Support - Luzhou benefits from the presence of Southwest Medical University, which is recognized as a national regional medical and health center, with seven disciplines ranked in the top 1% globally in ESI, particularly in geriatric and nuclear medicine [4][5]. - The integration of medical education and research with industry is highlighted as a solid foundation for supporting the silver economy [4]. Group 4: Practical Implementation - Luzhou has established a comprehensive community-based elderly care service model, recognized as a national typical case, which includes a full chain from "age-friendly renovations" to "smart devices" and "home services" [4]. - The city aims to systematically address common challenges in smart elderly care and the integration of medical and elderly care through national-level demonstrations [5].